Topic
340B
257 published works
To Be or Not to 340B Blog
CMS Proposal to Make One-Time $9 Billion Lump Sum Payment to 340B-Covered Entity Hospitals
By Brenda Maloney Shafer, Richard Davis, Michael French, Madison Hartman
The Centers for Medicare & Medicaid Services ("CMS") recently announced its proposal to make a one-time lump sum payment of roughly $9 billion to 340B-covered entity hospitals that were impacted…
Health Law Diagnosis
Connecticut Places Checks on PBM Contracts in Support of 340B Covered Entities
By Robinson+Cole's Health Law Group, Ivy Miller
On June 27, 2023, Connecticut Governor Ned Lamont signed into law Public Act 23-171“An Act Protecting Patients and Prohibiting Unnecessary Health Care Costs” (Act), which includes changes to the state’s…
Pharmacy & Healthcare Legal Blog
Recap of CSHA conference
Navigating the 340b universe: critical developments and practice points This year's conference organized by the California Society for Healthcare Attorneys was a success, as always. Thank you to all who…
Pharmacy & Healthcare Legal Blog
Recent Developments under 340B Program
Safety-net providers play a critical role in delivering healthcare services in this country. Recognizing their importance and to help them face escalating drug prices, Congress created the 340B Drug Pricing…
To Be or Not to 340B Blog
Continuing Changes in the 340B Space: New Restrictions and Shifting Alliances
By Brenda Maloney Shafer, Richard Davis, Michael French, Madison Hartman
As detailed further in our article on the current state of the 340B Program and what to expect in 2023, a growing list of manufacturers have taken the step of significantly restricting…
Health Care Law Today
The Future of the 340B Program: 2023 Key Decisions
By Anil Shankar, Stephanie J. Schwartz, Adria Warren
Critical decisions are pending before courts and legislators in 2023 that promise to shape the future of the 340B Drug Pricing Program (340B Program), which provides discounts on outpatient drugs…
Life Sciences Perspectives
340B Drug Pricing Program Reform Considerations
By Heath Ingram
The 340B Drug Pricing Program is a government program, administered by the Health Resources and Services Administration (HRSA), that allows qualifying hospitals and clinics that treat low-income and uninsured patients…
To Be or Not to 340B Blog
The Current State of 340B and What to Expect in 2023
By Brenda Maloney Shafer, Richard Davis, Michael French, Madison Hartman
2022 was an eventful year on the 340B front, packed with updates to consequential litigation, proposed new rules, ongoing uncertainty into the Health Resources and Services Administration's (HRSA) underlying enforcement…
Health Law
340B Contract Pharmacy Limits: The Conflict Continues
Third Circuit Rules on Manufacturer Restrictions on Contract Pharmacies The first of three pending appeals on whether a pharmaceutical manufacturer can limit distribution of covered 340B drugs to contract pharmacies…
Healthcare Perspectives
340B Underpayment Remedy Remanded to HHS
By Paul L. Croce, John W. Kaveney, James A. Robertson
As discussed in this prior blog post, beginning in 2018 the U.S. Department of Health and Human Services (HHS) reduced reimbursement rates for Medicare prescription drugs to 340B hospitals by…